1
Robin David Grey Cooper, Nancy June Snyder: Teicoplanin derivatives. Eli Lilly and Company, Arlene K Musser, June 29, 1999: US05916873 (32 worldwide citation)

The present invention is directed to teicoplanin derivatives of the following general formula, wherein R.sup.1 and R.sup.2 are as defined in the specification. ##STR1## These derivatives are useful as antibiotics for the control of gram-positive bacteria.


2
Jochen Ammenn, James Ronald Gillig, Lawrence Joseph Heinz, Philip Arthur Hipskind, Michael Dean Kinnick, Yen Shi Lai, John Michael Morin Jr, James Arthur Nixon, Carsten Ott, Kenneth Allen Savin, Theo Schotten, Lawrence John Slieker, Nancy June Snyder, Michael Alan Robertson: Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes. Eli Lilly and Company, Francis O Ginah, June 12, 2007: US07229987 (23 worldwide citation)

The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I); or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.


3
James Ronald Gillig, Lawrence Joseph Heinz, Michael Dean Kinnick, Yen Shi Lai, John Michael Morin, Nancy June Snyder: MCH receptor antagonists. Eli Lilly and Company, Francis O Ginah, November 7, 2006: US07132456 (18 worldwide citation)

The present invention relates to a melanin concentrating hormone antagonist compound of Formula I: (I) wherein Ar1, Ar2, Ar3, L1, L2 and Q areas defined, or a pharmaceutically acceptable salt, solvate, enantiomer or mixture of diastereomers thereof useful in the treatment, prevention or amelioration ...


4
Robert Edward Babine, Shu Hui Chen, Ivan Collado, Cristina Garcia Paredes, John Irvin Glass, Deqi Guo, Ling Jin, Jason Eric Lamar, Raymond Samuel Parker III, Nancy June Snyder, Xicheng David Sun, Mark Joseph Tebbe, Frantz Victor, Q May Wang, Yvonne Yee Mai Yip, Robert B Perni, Luc Farmer: Peptidomimetic protease inhibitors. Vertex Pharmaceuticals Incorporated, Honigman Miller Schwartz and Cohn, Jonathan P O Brien, Kathryn D Soulier, October 26, 2010: US07820671 (17 worldwide citation)

The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The in ...


5
Robert Edward Babine, Shu Hui Chen, Jason Eric Lamar, Nancy June Snyder, Xicheng Sun, Mark Joseph Tebbe, Frantz Victor, Q May Wang, Yvonne Yee Mai Yip, Ivan Collado, Cristina Garcia Paredes, Raymond Samuel Parker III, Ling Jin, Deqi Guo, John Irvin Glass: Peptidomimetic protease inhibitors. Vertex Pharmaceuticals Incorporated, Honigman Miller Schwartz and Cohn, Jonathan P O Brien, Kathryn D Soulier, August 28, 2012: US08252923 (10 worldwide citation)

The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The in ...


6
Robin David Grey Cooper, Michael John Rodriguez, Nancy June Snyder, Mark James Zweifel: Amides. Eli Lilly and Company, Arlene K Musser, July 6, 1999: US05919756 (6 worldwide citation)

The present invention is directed to amides of antibiotic A82846B (also known as chloroorienticin A), and of N.sup.4 -derivatives of A82846B. The present amide compounds are useful as antibacterials, especially for the control of gram positive bacteria; the compounds are particularly useful for the ...


7
Thomas Edward Mabry, Owen Brendan Wallace, Yanping Xu, Nancy June Snyder, Leonard Larry Winneroski Jr: Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1. Eli Lilly and Company, Dan L Wood, June 28, 2011: US07968585 (4 worldwide citation)

The present invention discloses novel compounds of Formula (I): having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the co ...


8
Thomas Daniel Aicher, Mark Joseph Chicarelli, Ronald Jay Hinklin, Hongqi Tian, Owen Brendan Wallace, John Gordon Allen, Zhaogen Chen, Thomas Edward Mabry, Jefferson Ray McCowan, Nancy June Snyder, Leonard Larry Winneroski Jr: Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1. Eli Lilly and Company, Dan L Wood, May 11, 2010: US07713979 (2 worldwide citation)

The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I ...


9
Robert Edward Babine, Shu Hui Chen, Ivan Collado, Cristina Garcia Paredes, John Irvin Glass, Ling Jin, Jason Eric Lamar, Raymond Samuel Parker III, Nancy June Snyder, Xicheng David Sun, Deqi Guo, Yvonne Yee Mai Yip, Q May Wang, Frantz Victor, Mark Joseph Tebbe, Robert B Perni, Luc Farmer: Peptidomimetic protease inhibitors. Vertex Pharmaceuticals Incorporated, Honigman Miller Schwartz and Cohn, Kathryn D Soulier, Jonathan P O Brien, September 10, 2013: US08529882

The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel stereoselective processes to intermediates. The i ...


10
Julie Kay Bush, Marvin Martin Hansen, Renhua Li, Thomas Edward Mabry, Nancy June Snyder, Owen Brendan Wallace, Yanping Xu: Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1. Eli Lilly and Company, Dan L Wood, April 10, 2012: US08153807

The present invention discloses novel compounds of Formula I: (I) having 11-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the c ...